1. Home
  2. JQC vs AVDL Comparison

JQC vs AVDL Comparison

Compare JQC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JQC
  • AVDL
  • Stock Information
  • Founded
  • JQC 2003
  • AVDL 2015
  • Country
  • JQC United States
  • AVDL Ireland
  • Employees
  • JQC N/A
  • AVDL N/A
  • Industry
  • JQC Finance Companies
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • JQC Finance
  • AVDL Health Care
  • Exchange
  • JQC Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • JQC 730.7M
  • AVDL 861.4M
  • IPO Year
  • JQC N/A
  • AVDL 1996
  • Fundamental
  • Price
  • JQC $5.42
  • AVDL $10.36
  • Analyst Decision
  • JQC
  • AVDL Strong Buy
  • Analyst Count
  • JQC 0
  • AVDL 6
  • Target Price
  • JQC N/A
  • AVDL $18.17
  • AVG Volume (30 Days)
  • JQC 714.6K
  • AVDL 1.6M
  • Earning Date
  • JQC 01-01-0001
  • AVDL 08-07-2025
  • Dividend Yield
  • JQC 11.13%
  • AVDL N/A
  • EPS Growth
  • JQC N/A
  • AVDL N/A
  • EPS
  • JQC N/A
  • AVDL N/A
  • Revenue
  • JQC N/A
  • AVDL $194,450,000.00
  • Revenue This Year
  • JQC N/A
  • AVDL $56.88
  • Revenue Next Year
  • JQC N/A
  • AVDL $29.81
  • P/E Ratio
  • JQC N/A
  • AVDL N/A
  • Revenue Growth
  • JQC N/A
  • AVDL 252.64
  • 52 Week Low
  • JQC $4.82
  • AVDL $6.38
  • 52 Week High
  • JQC $5.65
  • AVDL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • JQC 58.06
  • AVDL 63.54
  • Support Level
  • JQC $5.45
  • AVDL $8.74
  • Resistance Level
  • JQC $5.51
  • AVDL $9.56
  • Average True Range (ATR)
  • JQC 0.03
  • AVDL 0.37
  • MACD
  • JQC 0.00
  • AVDL 0.10
  • Stochastic Oscillator
  • JQC 66.67
  • AVDL 97.45

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: